GeneDx Holdings Corp. (WGS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GeneDx Holdings Corp. (WGS) has a cash flow conversion efficiency ratio of -0.119x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-28.98 Million) by net assets ($244.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see GeneDx Holdings Corp. stock valuation for the company's overall valuation and market capitalisation.
GeneDx Holdings Corp. - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how GeneDx Holdings Corp.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
GeneDx Holdings Corp. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GeneDx Holdings Corp. ranked by their cash flow conversion efficiency. Explore GeneDx Holdings Corp. earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beijing Venustech Inc
SHE:002439
|
0.005x |
|
Shenzhen Colibri Technologies Co Ltd
SHE:002957
|
0.026x |
|
Shenzhen Vital New Material Co. Ltd.
SHE:301319
|
N/A |
|
Shanghai Yuyuan Tourist Mart Co Ltd
SHG:600655
|
0.041x |
|
XiaMen HongXin Electron-tech Co Ltd
SHE:300657
|
-0.073x |
|
Ducommun Incorporated
NYSE:DCO
|
0.049x |
|
Inari Amertron Bhd
KLSE:0166
|
0.027x |
|
Hugo Boss AG
XETRA:BOSS
|
0.076x |
Annual Cash Flow Conversion Efficiency for GeneDx Holdings Corp. (2020–2025)
The table below shows the annual cash flow conversion efficiency of GeneDx Holdings Corp. from 2020 to 2025. View WGS stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $308.18 Million | $33.28 Million | 0.108x | +192.94% |
| 2024-12-31 | $245.25 Million | $-28.50 Million | -0.116x | +85.29% |
| 2023-12-31 | $228.02 Million | $-180.15 Million | -0.790x | +37.20% |
| 2022-12-31 | $253.71 Million | $-319.15 Million | -1.258x | -156.37% |
| 2021-12-31 | $388.10 Million | $-190.43 Million | -0.491x | +97.69% |
| 2020-12-31 | $4.39 Million | $-93.13 Million | -21.223x | -- |
About GeneDx Holdings Corp.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and can… Read more